Hypogonadism, Male
Conditions
Brief summary
To describe the rate of post-collection TU to testosterone conversion, as manifested by increases in testosterone concentration, in Plain tubes held at room temperature and sodium fluoride (NaF)-ethylenediaminetetraacetic acid (EDTA) tubes held at room temperature or on ice prior to centrifugation
Detailed description
This was an open-label, non-randomized, single-sequence study in which men dosed with JATENZO had blood drawn into 3 different types of blood-collection tubes (ie, Plain, EDTA, and NaF-EDTA). These tubes were then processed in different ways (ie, different durations between phlebotomy and centrifugation, different holding temperatures \[room temperature or on ice\] between phlebotomy and centrifugation). After defined periods of incubation, the tubes were centrifuged and the serum/plasma transferred into vials and frozen. The testosterone and TU levels in the serum/plasma were then measured using validated liquid chromatography/tandem mass spectrometry assays.
Interventions
DRUGTestosterone Undecanoate
dose was given orally and allowed to reach steady state
Sponsors
Celerion; Syneos Health; ARUP Laboratories
Clarus Therapeutics, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
Subjects were required to meet all of the following criteria in order to be eligible for the study: 1. Male (gender at birth) 18 to 65 years of age, inclusive, and legally able to give informed consent, as applicable by law. The percentage of non-Hispanic and Hispanic men was specified to be approximately ≥ 70% and ≤ 30%, respectively. 2. Adequate venous access in the left or right arm to allow collection of a number of blood samples via a venous cannula or needle sticks 3. Naïve to androgen-replacement therapy 4. Willing to consume the entire protocol-specified breakfast and dinner meals 5. Average screening systolic blood pressure \< 140 mmHg and/or diastolic blood pressure \< 90 mmHg 6. Voluntarily gave written informed consent to participate in this study -
Exclusion criteria
Subjects who met any of the following criteria were not eligible for participation in this study: 1. History of hypertension or taking anti-hypertensive medications 2. Intercurrent disease deemed clinically significant, in the opinion of the Investigator, of any type; in particular, liver, kidney, uncontrolled or poorly controlled heart disease, including congestive heart failure, coronary heart disease, heart attack or cerebrovascular accident in prior 6 months, or psychiatric-illness, including severe depression 3. Electrocardiogram which Principal Investigator, or designate, believed was clinically significantly abnormal 4. Intercurrent process or disease which could have impacted the absorption of JATENZO, in particular vomiting, nausea, diarrhea, or inflammatory bowel disease 5. Current use of the following groups of drugs that affect testosterone levels, testosterone metabolism, or levels of testosterone metabolites, namely antiandrogens, 5 alpha reductase inhibitors (eg, dutasteride, finasteride), estrogens, long-acting opioid analgesics (eg, methadone hydrochloride, buprenorphine hydrochloride), or human growth hormone 6. History of or was currently being evaluated for breast or prostate cancer 7. Prostate specific antigen above the upper limit of normal 8. Positive test for antibodies to human immunodeficiency virus type 1 or 2, hepatitis B surface antigen, or antibodies to hepatitis C virus at the Screening visit 9. Positive urine drug test at the Screening visit 10. Current treatment with oral lipase inhibitors (eg, orlistat \[Xenical\]), bile acid-binding resins (eg, cholestyramine \[Questran\], colestipol \[Colestid\]), fibric acid derivatives (eg, clofibrate \[Atromid-X\], gemfibrozil \[Lopid\]), and probucol (Lorelco). 11. Smokers who were unable to refrain from smoking during the confinement period required in this study 12. Current evidence of or history of abuse of alcohol or any drug substance within the previous 2 years 13. Receipt of any drug as part of a research study within 30 days of initial dose administration in this study 14. Blood donation (usually 550 mL) within the 12-week period before the initial study drug dose 15. Hematocrit \< 35% or \> 50% 16. Body mass index ≥ 31 kg/m2 -
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| measure rate of post-collection TU-to-testosterone conversion in 3 types of collection tubes | 8 days | To describe the rate of post-collection TU to testosterone conversion, as manifested by increases in testosterone concentration, in Plain tubes held at room temperature and sodium fluoride (NaF)-ethylenediaminetetraacetic acid (EDTA) tubes held at room temperature or on ice prior to centrifugation |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| rate of post-collection TU-to-testosterone conversion, as manifested by increases in testosterone concentration, in EDTA and NaF-EDTA collection tubes | 8 days | To describe the rate of post-collection TU to testosterone conversion, as manifested by increases in testosterone concentration, in EDTA and NaF-EDTA tubes held at room temperature or on ice prior to centrifugation |
| magnitude of overestimation of the true circulating testosterone concentration at 5 hours postdose | 8 days | To estimate the magnitude of overestimation of the true circulating testosterone concentration at 5 hours postdose, when blood was collected in various tubes and the tubes were held at room temperature or on ice. |
| healthy men's testosterone levels in serum and plasma | 8 days | To compare healthy men's testosterone levels in serum and plasma from Plain and EDTA tubes, respectively |
Other
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Treatment-Emergent Adverse Events | 8 days | To characterize the safety and tolerability of JATENZO |
Countries
United States
Outcome results
None listed